86
Views
1
CrossRef citations to date
0
Altmetric
Theme: Biomarkers: paving the way for better stratification in heart failure - Review

G-protein-coupled receptor kinases in cardiovascular conditions: focus on G-protein-coupled receptor kinase 2, a gain in translational medicine

&
Pages 525-540 | Published online: 08 Oct 2009

Bibliography

  • Pierce KL , PremontRT, LefkowitzRJ: Seven-transmembrane receptors.Nat. Rev. Mol. Cell Biol.3(9), 639–650 (2002).
  • Pitcher JA , FreedmanNJ, LefkowitzRJ: G protein-coupled receptor kinases.Annu. Rev. Biochem.67, 653–692 (1998).
  • Premont RT , IngleseJ, LefkowitzRJ: Protein kinases that phosphorylate activated G protein-coupled receptors.FASEB J.9(2), 175–182 (1995).
  • Willets JM , ChallissRA, NahorskiSR: Non-visual GRKs: are we seeing the whole picture?Trends Pharmacol. Sci.24(12), 626–633 (2003).
  • Metaye T et al. : Pathophysiological roles of G-protein-coupled receptor kinases.Cell. Signal17(8), 917–928 (2005).
  • Iaccarino G , CampanileA, SantulliG, ZuppieriF, KochWJ: G protein-coupled receptor kinases and hypertension: a review of disease mechanisms.High Blood Press Cardiovasc. Prev.13(4), 151–158 (2006).
  • Penela P , RibasC, MayorF Jr: Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell. Signal15(11), 973–981 (2003).
  • Gros R , BenovicJL, TanCM, FeldmanRD: G-protein-coupled receptor kinase activity is increased in hypertension.J. Clin. Invest.99(9), 2087–2093 (1997).
  • Usui I , ImamuraT, SatohHet al. : GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation.EMBO J.23(14), 2821–2829 (2004).
  • Ungerer M , BöhmM, ElceJS, ErdmannE, LohseMJ: Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart.Circulation87(2), 454–463 (1993).
  • Cross HR , SteenbergenC, LefkowitzRJ, KochWJ, MurphyE: Overexpression of the cardiac β2-adrenergic receptor and expression of a β-adrenergic receptor kinase-1 (βARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury.Circ. Res.85(11), 1077–1084 (1999).
  • Iaccarino G , KochWJ: Therapeutic potential of G-protein coupled receptor kinases in the heart.Expert Opin. Investig. Drugs8(5), 545–554 (1999).
  • Penela P , MurgaC, RibasC, TutorAS, PeregrínS, MayorF Jr: Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc. Res.69(1), 46–56 (2006).
  • Liggett SB , CresciS, KellyRJet al. : A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure.Nat. Med.14(5), 510–517 (2008).
  • Ribas C , PenelaP, MurgaCet al. : The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling.Biochim. Biophys. Acta1768(4), 913–922 (2007).
  • Anis Y , LeshemO, ReuveniHet al. : Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes.Diabetologia47(7), 1232–1244 (2004).
  • Usui I , ImamuraT, BabendureJLet al. : G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Gαq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes.Mol. Endocrinol.19(11), 2760–2768 (2005).
  • Cipolletta E , CampanileA, SantulliGet al. : The G protein coupled receptor kinase 2 plays an essential role in β-adrenergic receptor induced insulin resistance.Cardiovasc. Res. doi:10.1093/cvr/cvp252 (2009) (Epub ahead of print).
  • Michel MC , BroddeOE, InselPA: Peripheral adrenergic receptors in hypertension.Hypertension16(2), 107–120 (1990).
  • Michel MC , BeckeringhJJ, IkezonoK, KretschR, BroddeOE: Lymphocyte β2-adrenoceptors mirror precisely β2-adrenoceptor, but poorly β1-adrenoceptor changes in the human heart.J. Hypertens. Suppl.4(6), S215–S218 (1986).
  • Brodde OE , KretschR, IkezonoK, ZerkowskiHR, ReidemeisterJC: Human β-adrenoceptors: relation of myocardial and lymphocyte β-adrenoceptor density.Science231(4745), 1584–1585 (1986).
  • Iaccarino G , BarbatoE, CipollettaEet al. : Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure.Eur. Heart J.26(17), 1752–1758 (2005).
  • Dzimiri N , BascoC, MoorjiA, AfraneB, Al-HaleesZ: Characterization of lymphocyte β2-adrenoceptor signalling in patients with left ventricular volume overload disease.Clin. Exp. Pharmacol. Physiol.29(3), 181–188 (2002).
  • Park SJ , ChoiDJ, KimCW: Hypertensive left ventricular hypertrophy: relation to β-adrenergic receptor kinase-1 (βARK1) in peripheral lymphocytes.J. Hypertens.22(5), 1025–1032 (2004).
  • Hata JA , WilliamsML, SchroderJNet al. : Lymphocyte levels of GRK2 (βARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved β-adrenergic signaling after mechanical unloading.J. Card. Fail.12(5), 360–368 (2006).
  • Cohn JN , LevineTB, OlivariMTet al. : Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.N. Engl. J. Med.311(13), 819–823 (1984).
  • Lymperopoulos A , RengoG, KochWJ: Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation.Trends Mol. Med.13(12), 503–511 (2007).
  • Iaccarino G , BarbatoE, CipolettaE, FiorilloA, TrimarcoB: Role of the sympathetic nervous system in cardiac remodeling in hypertension.Clin. Exp. Hypertens.23(1–2), 35–43 (2001).
  • Iaccarino G , BarbatoE, CipolletaEet al. : Cardiac βARK1 upregulation induced by chronic salt deprivation in rats.Hypertension38(2), 255–260 (2001).
  • Iaccarino G , DolberPC, LefkowitzRJ, KochWJ: β-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by β- but not α1-adrenergic stimulation.Hypertension33(1 Pt 2), 396–401 (1999).
  • Iaccarino G , KeysJR, RapacciuoloAet al. : Regulation of myocardial βARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing α1β-adrenergic receptors.J. Am. Coll. Cardiol.38(2), 534–540 (2001).
  • Iaccarino G , TomhaveED, LefkowitzRJ, KochWJ: Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade.Circulation98(17), 1783–1789 (1998).
  • Reiter E , LefkowitzRJ: GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling.Trends Endocrinol. Metab.17(4), 159–165 (2006).
  • Bristow MR , GinsburgR, MinobeWet al. : Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts.N. Engl. J. Med.307(4), 205–211 (1982).
  • Lymperopoulos A , RengoG, FunakoshiH, EckhartAD, KochWJ: Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure.Nat. Med.13(3), 315–323 (2007).
  • Aggarwal A , EslerMD, SocratousF, KayeDM: Evidence for functional presynaptic α2-adrenoceptors and their down-regulation in human heart failure.J. Am. Coll. Cardiol.37(5), 1246–1251 (2001).
  • Rockman HA , KochWJ, LefkowitzRJ: Seven-transmembrane-spanning receptors and heart function.Nature415(6868), 206–212 (2002).
  • Dzimiri N , MuiyaP, AndresE, Al-HaleesZ: Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases.Eur. J. Pharmacol.489(3), 167–177 (2004).
  • Leineweber K , RoheP, BeilfussAet al. : G-protein-coupled receptor kinase activity in human heart failure: effects of β-adrenoceptor blockade.Cardiovasc. Res.66(3), 512–519 (2005).
  • Martini JS , RaakeP, VingeLEet al. : Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes.Proc. Natl Acad. Sci. USA105(34), 12457–12462 (2008).
  • Sorriento D , CiccarelliM, SantulliGet al. : The G-protein-coupled receptor kinase 5 inhibits NF-κB transcriptional activity by inducing nuclear accumulation of IκBα.Proc. Natl Acad. Sci. USA105(46), 17818–17823 (2008).
  • Koch WJ , RockmanHA, SamamaPet al. : Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor.Science268(5215), 1350–1353 (1995).
  • Rockman HA , ChienKR, ChoiDJet al. : Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice.Proc. Natl Acad. Sci. USA95(12), 7000–7005 (1998).
  • Harding VB , JonesLR, LefkowitzRJ, KochWJ, RockmanHA: Cardiac βARK1 inhibition prolongs survival and augments β-blocker therapy in a mouse model of severe heart failure.Proc. Natl Acad. Sci. USA98(10), 5809–5814 (2001).
  • Tachibana H , Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA: Level of β-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation111(5), 591–597 (2005).
  • Swedberg K , BristowMR, CohnJNet al. ; Moxonidine Safety and Efficacy (MOXSE) investigators: Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation105(15), 1797–1803 (2002).
  • Chobanian AV , BakrisGL, BlackHRet al. : Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension42(6), 1206–1252 (2003).
  • Harris DM , CohnHI, PesantS, EckhartAD: GPCR signalling in hypertension: role of GRKs.Clin. Sci. (Lond.)115(3), 79–89 (2008).
  • Iaccarino G , CipollettaE, FiorilloAet al. : β2-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension.Circulation106(3), 349–355 (2002).
  • Gros R , TanCM, ChorazyczewskiJ, KelvinDJ, BenovicJL, FeldmanRD: G-protein-coupled receptor kinase expression in hypertension.Clin. Pharmacol. Ther.65(5), 545–551 (1999).
  • Gros R , ChorazyczewskiJ, MeekMD, BenovicJL, FergusonSS, FeldmanRD: G-protein-coupled receptor kinase activity in hypertension : increased vascular and lymphocyte G-protein receptor kinase-2 protein expression.Hypertension35(1 Pt 1), 38–42 (2000).
  • Eckhart AD , OzakiT, TevaearaiH, RockmanHA, KochWJ: Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates β-adrenergic receptor signaling and increases resting blood pressure.Mol. Pharmacol.61(4), 749–758 (2002).
  • Liu S , PremontRT, KontosCD, ZhuS, RockeyDC: A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension.Nat. Med.11(9), 952–958 (2005).
  • Leosco D , IaccarinoG, CipollettaEet al. : Exercise restores β-adrenergic vasorelaxation in aged rat carotid arteries.Am. J. Physiol. Heart Circ. Physiol.285(1), H369–H374 (2003).
  • Izzo R : Enhanced GRK2 expression and desensitization of βAR vasodilatation in hypertensive patients.Clin. Transl. Sci.1(3) (2008).
  • Banday AA , LokhandwalaMF: Oxidative stress reduces renal dopamine D1 receptor-Gq/11α G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2.Am. J. Physiol. Renal Physiol.293(1), F306–F315 (2007).
  • Trivedi M , LokhandwalaMF: Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats.Am. J. Physiol. Renal Physiol.289(2), F298–F304 (2005).
  • Keys JR , ZhouRH, HarrisDM, DruckmanCA, EckhartAD: Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling.Circulation112(8), 1145–1153 (2005).
  • Premont RT , MacraeAD, StoffelRHet al. : Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants.J. Biol. Chem.271(11), 6403–6410 (1996).
  • Sanada H , JosePA, Hazen-MartinDet al. : Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension.Hypertension33(4), 1036–1042 (1999).
  • Choi DJ et al. : Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase.J. Biol. Chem.272(27), 17223–17229 (1997).
  • Manning BS , ShotwellK, MaoL, RockmanHA, KochWJ: Physiological induction of a β-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy.Circulation102(22), 2751–2757 (2000).
  • Anderson KM , EckhartAD, WilletteRN, KochWJ: The myocardial β-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats.Hypertension33(1 Pt 2), 402–407 (1999).
  • Eckhart AD , KochWJL: Expression of a β-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes.Mol. Ther.5(1), 74–79 (2002).
  • Eckhart AD , DuncanSJ, PennRB, BenovicJL, LefkowitzRJ, KochWJ: Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart.Circ. Res.86(1), 43–50 (2000).
  • Matkovich SJ , DiwanA, KlankeJLet al. : Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β-adrenergic signaling.Circ. Res.99(9), 996–1003 (2006).
  • Fox KF , CowieMR, WoodDAet al. : Coronary artery disease as the cause of incident heart failure in the population.Eur. Heart J.22(3), 228–236 (2001).
  • Ungerer M , KessebohmK, KronsbeinK, LohseMJ, RichardtG: Activation of β-adrenergic receptor kinase during myocardial ischemia.Circ. Res.79(3), 455–460 (1996).
  • Lasley RD , MentzerRM Jr: Pertussis toxin blocks adenosine A1 receptor mediated protection of the ischemic rat heart. J. Mol. Cell. Cardiol.25(7), 815–821 (1993).
  • Chen EP , BittnerHB, AkhterSA, KochWJ, DavisRD: Myocardial recovery after ischemia and reperfusion injury is significantly impaired in hearts with transgenic overexpression of β-adrenergic receptor kinase.Circulation98(19 Suppl.), II249–II253; discussion II253–II254 (1998).
  • Yu X , ZhangM, KykerK, PattersonE, BenovicJL, KemDC: Ischemic inactivation of G protein-coupled receptor kinase and altered desensitization of canine cardiac β-adrenergic receptors.Circulation102(20), 2535–2540 (2000).
  • Yu X , HuangS, PattersonEet al. : Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.Am. J. Physiol. Heart Circ. Physiol.289(5), H1960–H1967 (2005).
  • Tong H , RockmanHA, KochWJ, SteenbergenC, MurphyE: G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning.Circ. Res.94(8), 1133–1141 (2004).
  • Akhter SA , D‘SouzaKM, PetrashevskayaNN, Mialet-PerezJ, LiggettSB: Myocardial β1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury.Am. J. Physiol. Heart Circ. Physiol.290(4), H1427–H1432 (2006).
  • Piscione F , IaccarinoG, GalassoGet al. : Effects of Ile164 polymorphism of β2-adrenergic receptor gene on coronary artery disease.J. Am. Coll. Cardiol.52(17), 1381–1388 (2008).
  • Raake PW , VingeLE, GaoEet al. : G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure.Circ. Res.103(4), 413–422 (2008).
  • Vasan RS : Biomarkers of cardiovascular disease: molecular basis and practical considerations.Circulation113(19), 2335–2362 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.